Palatin reports FY2023 net loss $27.5M; Vyleesi net revenue up 298%; PL9643 fully enrolled

PALATIN TECHNOLOGIES INC

Net loss of $27.5M ($2.53 diluted EPS) for FY2023 vs $36.2M loss ($3.79 EPS) in FY2022.
Vyleesi net product revenue $4.9M in FY2023, up 298% YoY; Q4 net revenue $1.8M, up 128%.
Phase 3 PL9643 (dry eye) fully enrolled (570 patients); topline data expected late Q4 2023.
Phase 2 PL8177 (ulcerative colitis) interim analysis targeted Q1 2024; topline H1 2024.
Cash $11.0M plus $2.9M receivables as of June 30; audit includes going concern paragraph.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PALATIN TECHNOLOGIES INC reported financial results for fiscal year ended June 30, 2023.

Period: fiscal year ended June 30, 2023
Result: reported results

Exact text from the filing

On September 28, 2023, we issued a press release including results for our fiscal year ended June 30, 2023 and announcing a teleconference and webcast to be held September 28, 2023, at 11:00 a.m. Eastern time, which will include a discussion on results of operations in greater detail and an update on corporate developments.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PALATIN TECHNOLOGIES INC reported financial results for fiscal fourth quarter ended June 30, 2023.

Period: fiscal fourth quarter ended June 30, 2023
Result: reported results

Exact text from the filing

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced financial results for its fiscal fourth quarter and fiscal year ended June 30, 2023.

View on SEC.gov

Browse all earnings releases →

PALATIN TECHNOLOGIES INC filing history →

Source: SEC EDGAR

accession 0001654954-23-012336

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.